Endocrine Abstracts

With over 500,000 fragility fractures a year and an ageing demographic, tackling the burden of osteoporosis is an urgent national priority. Effective secondary fracture prevention within the NHS could prevent over 20,000 fragility fractures including 9,000 hip fractures within 5 years. Ensuring this care gap is closed requires support from political prioritisation, business case models, getting started and getting improved and sustainable. This presentation will highlight the ...

With over 500,000 fragility fractures a year and an ageing demographic, tackling the burden of osteoporosis is an urgent national priority. Effective secondary fracture prevention within the NHS could prevent over 20,000 fragility fractures including 9,000 hip fractures within 5 years. Ensuring this care gap is closed requires support from political prioritisation, business case models, getting started and getting improved and sustainable. This presentation will highlight the ...

UX023-CL303 is an ongoing, Phase 3, double-blind, multicenter study examining the efficacy and safety of burosumab, a fully human monoclonal antibody against FGF23, in adults with XLH. Eligible subjects had serum phosphorus levels <0.81 mmol/l and skeletal pain (BPI – Worst Pain ≥4). Subjects (N=134) were randomized 1:1 to receive burosumab 1 mg/kg or placebo subcutaneously every 4 weeks. After 24 weeks, subjects in the placebo group crossed-over to rec...